On March 4, 2024, several groups of scientists discussed the challenges of investigating the effects of HIV in the central nervous system (CNS) at the oral abstract session on neuropathogenesis of HIV held during the 31st Conference on Retroviruses and Opportunistic Infections (CROI), in Denver. A cure for HIV will require eliminating the virus in all its reservoirs, those tissues where HIV remains latent but retains the capacity for reactivation and replication. However, despite antiretroviral therapy (ART), the virus could continue to replicate continuously at a low level in some reservoirs, including the CNS.

A male patient who harbored a deletion in the intron 7-exon 8 region of the dystrophin gene, DMD, was showing symptoms that matched with Becker muscular dystrophy.

Researchers from Alumis Inc. have presented preclinical data for a novel, potential first-in-class tyrosine kinase 2 (TYK2) inhibitor – A-005.

Semaphorin 3A signaling, through the plexin A1/neuropilin 1 (PLXA1/NRP1) receptor complex, is known to disrupt the differentiation and migration of oligodendrocyte precursor cells and mature remyelinating oligodendrocytes. Both semaphorin 3A and plexin A1 are up-regulated in the central nervous system of patients with multiple sclerosis.

Researchers from University of Padova have presented data from a study that aimed to investigate the role of microRNAs (miRs) in the development and progression of inflammatory bowel disease (IBD)-related colorectal cancer (CRC).

Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.

The efficacy of anti-inflammatory therapies used for treating inflammatory bowel disease (IBD) is still not optimal.